Healthcare AI growth rounds priced at a median 8.4x forward revenue in the first half of 2026, down from 11.2x twelve months earlier, according to PitchBook data reported by Yanne Capital Research. A separate Yanne Capital note puts the 2025 comparison even more starkly: growth-stage healthcare AI rounds closed at a median 9.2x forward ARR against 4.5x for non-AI healthtech and 11.8x for horizontal generative AI infrastructure in the same period, per their healthcare AI equity trajectory analysis.
Multiple compression sounds like bad news for founders, and in aggregate it is. But the headline number, again, is hiding the number that matters. The compression is not evenly distributed. Yanne Capital is explicit that the split runs along a specific line: companies with at least one signed enterprise health system contract above a meaningful revenue threshold are being priced entirely differently than companies without one.
Where the multiples actually sit by category
Windsor Drake's Q1 2026 AI in healthcare valuations research breaks the category down further, and the spread by function is wide enough that treating "healthcare AI" as a single valuation category is a mistake in itself:
| Category | EV/Revenue multiple range |
|---|---|
| Drug discovery and development platforms | 8x to 15x |
| Clinical workflow AI with signed enterprise contracts | Premium end of the range |
| RCM and operations AI | 3x to 6x |
| General "AI-enabled" healthtech without differentiated data or contracts | Compressed toward non-AI healthtech multiples |
Windsor Drake also notes that regulatory status, specifically FDA clearance through 510(k), De Novo or PMA, drives an incremental valuation uplift independent of revenue, which tells you investors are pricing regulatory moat as a distinct asset from commercial traction, not a substitute for it.
Why the compression happened at all
Two things happened at once. First, the initial wave of generative AI enthusiasm in healthcare priced almost anything with "AI" in the deck at a premium in 2023 and 2024, and that premium was never going to survive a market that started asking for renewal data. Second, Carta's Q1 2026 report on private markets found more than 60 percent of all venture dollars flowing to AI companies broadly, which means the AI premium concentrated even further into fewer, larger, better-evidenced deals, exactly the mega-round pattern also visible in the wider digital health funding data.
A useful framing from an analysis of platform versus wrapper valuation dynamics in healthcare AI is that falling foundation-model inference costs and the proliferation of open-source models are deflating the value of thin application layers built on top of someone else's model, while genuinely differentiated platforms, ones with proprietary clinical data, deployed workflow integration or regulatory clearance, are holding their multiple.
What this means if you are a healthcare AI founder raising right now
Being "AI-enabled" is no longer a valuation argument on its own. The premium has migrated to companies that can show a defensible data or workflow moat, not to companies that added a model to an existing product category.
A signed enterprise contract is worth more to your multiple than your model's benchmark score. Investors have enough pattern-matching now to discount a strong demo and reward a renewing customer.
Category matters more than the "AI" label. A clinical-workflow AI company with enterprise contracts, a drug-discovery platform, and an RCM automation tool are pricing in three different bands entirely, and pitching your company as generically "healthcare AI" without specifying which of these you actually are will get you benchmarked against the wrong comp set, usually to your disadvantage.
Regulatory clearance is being priced as an asset. If a 510(k) or De Novo pathway is realistic for your product, the Windsor Drake data suggests investors will pay for it ahead of revenue scale, not just after.
The takeaway
The healthcare AI multiple story of 2025 to 2026 is not "AI is out of favor." It is that the market has finished its first real diligence cycle on the category and started pricing the difference between a company that sells into healthcare with a defensible position and a company that sells a thin AI feature into a market with no switching cost. If your fundraising materials cannot show which one you are, the market will assume the cheaper answer.
